The comparative analysis of antiparkinsonian activity of glycine combined with amantadine in conditions of changing neurosynaptic transmission.

V. I. Mamchur, T. N. Kryvoruchko, O. V. Makarenko


Parkinson's disease is traditionally viewed as a disease which affects the human motor sphere. Besides motor manifestations in the clinical picture of the disease, non-motor manifestations with dementia as the most common are present. The purpose of the work – experimental evaluation of the possible antiparkinsonian action of glycine in terms of experimental models of Parkinson's disease equivalents (akinetic-rigid and tremor forms) on the background of antiparkinsonian correction by amantadine. Methods: catalepsy model (inhibition of dopaminergic transmission, equivalents of hypokinesia and rigidity states) and model of arekolyn tremor (activation of cholinergic transmission that corresponds to parkinsonian tremor) on the background of amantadine administration (50 mg/kg), glycine (100 mg/kg and 200 mg/kg) and their combined introduction.The research results show a positive dynamic in combined using of amantadine with glycine at a dose of 100 mg/kg and 200 mg/kg, which was is determined by the low percentage of animals with symptoms of catalepsy (50-70%) with evaluation criteria of 0.5-1.8 points with maximum possible 6 points. Similar results were obtained in terms of activation of the cholinergic system (arekolyn tremor). Glycine at a dose of 100 mg/kg and 200 mg/kg facilitated to optimization of antitremor action of amantadine, that is registered in increased latent period of tremor, reduction of its duration and intensity attenuation almost by 2,1 times in comparison with indicators of the control group. Thus, studied combinations of amantadine with glycine at a dose of 100 mg/kg and 200 mg/kg are promising in studying of their influence on dementia in Parkinson's syndrome, and this study will be continued.


Parkinson's syndrome; catalepsy; tremor; amantadine; glycine

Full Text:



1. Karaban YN, Karaban NV, Karasevych NV. [Blo­ckers of glutamate receptors (Neomidantan) in the pathogenetic therapy of Parkinson's disease and other neurologic diseases (guidelines)].Kyiv. 2004;24. Russian.

2. Lapach SN, Chubenko AV, Babych PN. [Statis­tical methods in biomedical research using EXCEL]. Kyiv. Moryon, 2001;408. Ukrainian.

3. Makarenko OV, Mamchur VI. [Modern view on preclinical study of antiparkinsonian drugs]. Liky. 2007;3-4:3-11. Ukrainian.

4. MamchurVI, MakarenkoOV, DronovSM. [Al­go­rithm of preclinical evaluation (general pharmacology, specific activity) of antiparkinsonian drugs. Guidelines]. Kyiv. 2009;21. Ukrainian.

5. StrachunskaiaEIa. [Parkinsonism from the stand­point of modern information concepts of medicine]. Smolensk. 2008;208. Russian

6. TrufanovEA,HolovchenkoYuY, SlobodynTN, SukhoverskaiaON. [Epidemiology of Parkinson's disease in Ukraine].Mezhdunarodniinevrolohycheskyizhurnal. 2012;7(53). Russian.

7. BaileyM, GoldmanJG. CharacterizingCognitiveImpairmentinParkinsonsDisease.SeminNeurol. 2017;37(2):167-75.

8. Cervetto C, Taccola G.GABAA and strychnine-sensitive glycine receptors modulate N-methyl-D-aspar­tate-evoked acetylcholine release from rat spinal moto­neurons: a possible role in neuroprotection. Neuroscience. 2008;154(4):1517-24.

9. Connolly BS, Lang AE. Pharmacological treat­ment of Parkinson disease: a review. JAMA. 2014;311(16):1670-83.

10. KvrivishviliG. Glycineandneuroprotectiveef­fectofhypothermiainhypoxic-ischemicbraindamage. Neuroreport. 2002;13(16):1995-2000.

11. Wang GH, Jiang ZL, Fan XJ, Zhang L, Li X, Ke KF.Neuroprotective effect of taurine against focal cerebral ischemia in rats possibly mediated by activation of both GABAA and glycine receptors. Neuropha­rmacology. 2007;52(5):1199-209.

GOST Style Citations

  1. Карабань И.Н. Блокаторы глутаматных рецеп­торов (Неомидантан) в патогенетической терапии бо­лезни Паркинсона и других неврологиченских заболе­ваний (метод. рекомендации) / И.Н. Карабань, Н.В. Ка­рабань, Н.В. Карасевич. – Киев, 2004. – 24 с.
  2. Лапач С.Н. Статис­тические методы в медико-биологических исследованиях с использованием EXCEL / С.Н. Лапач, А.В. Чубенко, П.Н. Бабич. – Киев: Морион, 2001. – 408 с.
  3. Макаренко О.В. Сучасний погляд на доклі­нічне вивчення антипаркінсонічних засобів / О.В. Ма­каренко, В.Й. Мамчур / Ліки. – 2007. – № 3-4. – С. 3-11
  4. Мамчур В.Й. Алгоритм доклінічної оцінки (за­гальна фармакологія, специфічна активність) анти­паркінсонічних засобів: метод. рекомендації / В.Й. Мамчур, О.В. Макаренко, С.М. Дронов. – Київ, 2009. – 21 с.
  5. Страчунская Е.Я. Паркинсонизм с позиций современных информационных концепций медицины / Е.Я. Страчунская. – Смоленск, 2008. – 208 с.
  6. Эпидемиология болезни Паркинсона в Украине / Е.А. Труфанов, Ю.И. Головченко, Т.Н. Сло­бодин, О.Н. Суховерская // Междунар. неврол. жур­нал. – 2012. – № 7 (53). Электронный доступ [].
  7. Bailey M. Characterizing Cognitive Impairment in Parkinsons Disease / Bailey M., Goldman J.G. // Semin Neurol. – 2017. – Vol. 37, N 2. – P. 167-175. 
  8. Cervetto C. GABAA and strychnine-sensitive glycine receptors modulate N-methyl-D-aspartate-evoked acetylcholine release from rat spinal motoneurons: a possible role in neuroprotection // C. Cervetto, G. Taccola / Neuroscience. – 2008. – Vol. 154, N 4. – Р. 1517-1524.
  9. Connolly B.S. Pharmacological treatment of Par­kinson disease: a review / B.S. Connolly, A.E. Lang // JAMA. – 2014. – Vol. 311, N 16. – P. 1670-1683.
  10. Kvrivishvili G. Glycine and neuroprotective ef­fect of hypothermia in hypoxic-ischemic brain damage / G. Kvri­vishvili // Neuroreport. - 2002. – N 13, N 16. – Р. 1995-2000.
  11.  Neuroprotective effect of taurine against focal cerebral ischemia in rats possibly mediated by activation of both GABAA and glycine receptors / G.H. Wang, Z.L. Jiang, X.J. Fan, L. Zhang [et al.] // Neuropharmacol. – 2007. – Vol. 52, N 5. –Р. 1199-1209.



  • There are currently no refbacks.